Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Targeted Quality Improvement Trial to Improve Post-Discharge VTE

18. november 2026 opdateret af: University of Chicago

Targeted Quality Improvement Trial to Improve Post-Discharge VTE Chemoprophylaxis After Abdominal and Pelvic Cancer Surgery

Venous thromboembolism (VTE) is the most common preventable cause of death after major abdominal and pelvic cancer surgery, and over one-third of events occur after discharge. National guidelines recommend extended post-discharge chemoprophylaxis, but hospital adherence varies widely. This observational study has two parts. Aim 1 uses interviews, focus groups, and surveys with patients, clinicians, and health system stakeholders to identify barriers and facilitators to implementing a post-discharge VTE chemoprophylaxis quality improvement project. Aim 2 uses retrospective hospital- and population-level data and coincidence analysis to identify hospital performance phenotypes and develop targeted implementation strategies. Findings will inform a separately registered stepped-wedge implementation trial (Aim 3).

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Detaljeret beskrivelse

Aim 1: Semi-structured interviews, focus groups, and electronic surveys will be conducted with patients (n≈20) undergoing abdominal or pelvic cancer surgery, clinicians (n≈20), and health system stakeholders (n≈10). Surveys include study-specific VTE chemoprophylaxis and ordering surveys, the Organizational Readiness to Change Assessment (ORCA), and the Safety Attitudes Questionnaire (SAQ). Interviews are audio-recorded, transcribed, de-identified, and analyzed with hybrid inductive and deductive coding mapped to CFIR domains. Patient eligibility is screened through the medical record; screening data are not linked to survey or interview responses.

Aim 2: De-identified, retrospective hospital- and population-level data (demographics, procedure details, VTE prophylaxis orders, VTE outcomes), obtained through the University of Chicago Center for Research Informatics, will be analyzed using coincidence analysis (CNA) to identify causal pathways, define low- and high-performance hospital phenotypes, and develop targeted implementation strategies. Aim 2 data are kept separate from Aim 1 recruitment data.

This record covers Aims 1 and 2 only. The Aim 3 stepped-wedge trial is registered separately

Undersøgelsestype

Observationel

Tilmelding (Anslået)

80

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Illinois
      • Chicago, Illinois, Forenede Stater, 60637
        • University of Chicago
        • Kontakt:
        • Ledende efterforsker:
          • Ryan P Merkow, MD, MS

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients, clinicians, and health system stakeholders involved in abdominal and pelvic cancer surgery care, plus a retrospective hospital-level dataset.

Beskrivelse

Inclusion Criteria:

  • Patients: adults (18-85) undergoing abdominal and/or pelvic cancer surgery; English-speaking
  • Clinicians: faculty and fellow physicians, advanced practice providers, physician assistants, medical assistants, dietitians, and social workers in participating surgical service clinics; English-speaking
  • Stakeholders: Chief Medical Officer, Chief Information Officer, Chief Quality Officer, or related leadership

Aim 2: records of patients undergoing abdominal or pelvic cancer surgery between 1/1/2006 and 9/16/2025

Exclusion Criteria:

  • Non-English-speaking individuals
  • Patients not undergoing abdominal or pelvic cancer surgery
  • Individuals under 18

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: OTHER
  • Tidsperspektiver: OTHER

Kohorter og interventioner

Gruppe / kohorte
Patients

Adults undergoing abdominal or pelvic cancer surgery at the University of Chicago Medical Center, interviewed or surveyed about post-discharge VTE chemoprophylaxis.

Clinicians

Surgeons, advanced practice providers, nurses, and other clinical staff who care for abdominal and pelvic cancer surgery patients, interviewed or surveyed.

Health System Stakeholders

Chief Medical, Information (or Medical Information), and Quality Officers and related leadership, interviewed.

Retrospective Hospital/Patient Dataset (Aim 2)

De-identified, hospital- and population-level records of abdominal and pelvic cancer surgery patients, 2006-2025

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Barriers and facilitators to post-discharge VTE chemoprophylaxis implementation
Tidsramme: Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.

Themes identified from interviews and focus groups, coded and mapped to CFIR domains

Year 1 and 2; Single interview or focus group session (30-60 minutes), at enrollment.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Organizational readiness to change (ORCA score)
Tidsramme: Year 1 and 2; Single survey at enrollment.

Survey scores, dichotomized as low or high

Year 1 and 2; Single survey at enrollment.
Safety and quality culture (SAQ score)
Tidsramme: Year 1 and 2; Single survey at enrollment.

Survey scores, dichotomized as low or high.

Year 1 and 2; Single survey at enrollment.
VTE chemoprophylaxis ordering patterns
Tidsramme: Year 1 and 2; Single survey at enrollment.

Survey responses on type of prophylaxis prescribed, reasoning, and risk factors.

Year 1 and 2; Single survey at enrollment.
Hospital performance phenotypes
Tidsramme: Year 3; Following AIM 2 completion.

Number and characteristics of low- and high-performance phenotypes identified by coincidence analysis of Aim 1 and retrospective data.

Year 3; Following AIM 2 completion.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Ryan Merkow, MS, MD, University of Chicago

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. januar 2027

Primær færdiggørelse (Anslået)

1. januar 2028

Studieafslutning (Anslået)

1. januar 2029

Datoer for studieregistrering

Først indsendt

10. november 2026

Først indsendt, der opfyldte QC-kriterier

18. november 2026

Først opslået (Faktiske)

20. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

20. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IRB25-1360
  • R01HL183429 (U.S. NIH-bevilling/kontrakt)
  • IRB25-1360 (Anden identifikator: UChicago IRB)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

UBESLUTET

IPD-planbeskrivelse

Qualitative recordings and transcripts will not be shared. De-identified data will be retained in secure University of Chicago storage, and any external sharing would require IRB review

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .